Phuturdex › Diseases › Colitis
Drugs in development · updated 30 October 2026
Colitis: drugs in development
As of 30 October 2026 there are 20 active clinical trials (recruiting or ongoing, phases I–III) on 24 drugs for colitis. 9 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Probiotics 6600 | II–III | 1 | NCT07047339 |
| SPY001 | II | 2 | NCT07652294 |
| SPY002 | II | 2 | NCT07652294 |
| SPY003 | II | 2 | NCT07652294 |
| ATH-063 | II | 1 | NCT07513181 |
| Eltrekibart | II | 1 | NCT06598943 |
| PALI-2108 | II | 1 | NCT07845487 |
| KAN-004 | I | 1 | NCT07196410 |
| R-3750 | I | 1 | NCT05666960 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| VedolizumabEntyvio® | II–III | 6 | NCT06337695 |
| InfliximabZymfentra®, Avsola® | III | 5 | NCT05947669 |
| MethylprednisoloneMethylprednisolon, Methylprenisolone | III | 3 | NCT05947669 |
| ModafinilProvigil® | II–III | 1 | NCT07582458 |
| PrednisolonePrednisolon, Prenisolone | III | 1 | NCT05947669 |
| PrednisonePredinisone, Cortancyl | II | 3 | NCT04305145 |
| AzathioprineImuran, Jayempi® | II | 1 | NCT07619898 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 1 | NCT03219359 |
| EtrasimodVelsipity® | II | 1 | NCT07470879 |
| MethoxsalenUvadex, Oxsoralen-Ultra® | II | 1 | NCT07619898 |
| MirikizumabOmvoh® | II | 1 | NCT06598943 |
| Mycophenolate MofetilMycophenolate, Cellcept | II | 1 | NCT07619898 |
| ThymoglobulinRabbit Anti thymocyte globulin, Rabbit ATG | II | 1 | NCT03219359 |
| VancomycinTyzavan®, Firvanq Kit® | II | 1 | NCT07646223 |
| LoperamideImodium A-D Ez Chews®, Imodium A-D® | I | 1 | NCT04038619 |
Sorted by most advanced phase and number of active trials.
All 24 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Ulcerative colitis 99 drugs
- Crohn's disease 81 drugs
- Inflammatory bowel diseases 69 drugs
- Psoriatic arthritis 48 drugs
- Gastrointestinal disease 22 drugs
- Renal cell carcinoma 228 drugs
- Non-small-cell lung carcinoma 726 drugs
- Melanoma 352 drugs
- Hepatocellular carcinoma 266 drugs
- Esophageal neoplasm 191 drugs
- Squamous cell carcinoma 72 drugs
- Uterine cervix neoplasm 224 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Gastrointestinal disease 22 drugs
- Colonic disease 11 drugs
- Intestinal disease 15 drugs
- Gastroenteritis 4 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003092 “Colitis”.